2022年(nian)的政府工作(zuo)報告提出,支持中(zhong)醫(yi)藥振(zhen)興發展,推進中(zhong)醫(yi)藥綜(zong)合改革。在國(guo)家(jia)頂層政策(ce)支持、國(guo)際(ji)化(hua)等大背景下,中(zhong)醫(yi)藥行業有著巨(ju)大的成(cheng)長(chang)空間,各(ge)細分領域將迎來黃(huang)金發展期。米內網數據顯示,預計(ji)2021年(nian)中(zhong)國(guo)城(cheng)市實(shi)體藥店婦科中(zhong)成(cheng)藥市場規(gui)模(mo)超過50億元。
從TOP20廠家格局來看,株洲千金(jin)藥(yao)(yao)(yao)業、山西廣譽遠國藥(yao)(yao)(yao)、九芝(zhi)(zhi)堂(tang)、仲景宛(wan)西制藥(yao)(yao)(yao)、四川(chuan)恩(en)威制藥(yao)(yao)(yao)位居前五。產品TOP20中(zhong)(zhong)10個是獨家,5個漲超10%。在(zai)(zai)中(zhong)(zhong)國城市實體藥(yao)(yao)(yao)店(dian)婦(fu)科中(zhong)(zhong)成藥(yao)(yao)(yao)產品TOP20中(zhong)(zhong),九芝(zhi)(zhi)堂(tang)驢膠補(bu)(bu)血(xue)顆(ke)粒占市場份額(e)3.45%,位居第(di)四;在(zai)(zai)中(zhong)(zhong)國城市實體藥(yao)(yao)(yao)店(dian)婦(fu)科中(zhong)(zhong)成藥(yao)(yao)(yao)品牌TOP20中(zhong)(zhong),九芝(zhi)(zhi)堂(tang)驢膠補(bu)(bu)血(xue)顆(ke)粒占市場份額(e)3.39%,位居第(di)五。